Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2023-06-30 Capital/Financing Update
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 29, 2023, by CytomX Therapeutics, Inc. It reports the entry into a material definitive agreement related to a private placement of warrants and common stock. The content focuses on the details of the financing transaction, including terms of the warrants, exercise prices, and expected proceeds. There are no financial statements or comprehensive financial performance data included, nor is this a transcript, management discussion, or annual/interim report. The primary subject is an update on a capital raising event and related securities issuance. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length and detail support a confident classification.
2023-06-30 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by CytomX Therapeutics, Inc. It specifically reports the submission of matters to a vote of security holders at the 2023 Annual Meeting of Stockholders, including detailed voting results for director elections, auditor ratification, and executive compensation advisory vote. The content focuses on official voting results from the Annual Meeting, not the meeting materials or the full annual report. The document length is 4438 characters, which is relatively short but contains substantive voting data. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-06-20 English
Director's Dealing 2023
Director's Dealing
2023-06-16 English
Director's Dealing 2023
Director's Dealing
2023-06-16 English
Director's Dealing 2023
Director's Dealing
2023-06-16 English
Director's Dealing 2023
Director's Dealing
2023-06-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.